Abstract
The COVID-19 outbreak originated at the end of 2019 from Wuhan [1, 2], a city in Hubei province in central China. According to the World Health Organization (WHO), there were 88,948 confirmed cases and 3,043 deaths from 65 countries as of March 2, 2020. In China, the outbreak has effectively confined over 1 billion people to their apartments and homes since the end of January 2020 and continues to disrupt healthcare, wellbeing, and the economy. As the situation in China appears to be stabilizing, sharp increases in confirmed cases are being reported in South Korea, Italy, Japan, and Iran.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Source code and data are publically available on GitHub.
